Anti-SARS-CoV-2 immunoadhesin remains effective against Omicron and other emerging variants of concern.
Biological sciences
Health sciences
Immunology
Virology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
21 Oct 2022
21 Oct 2022
Historique:
received:
18
01
2022
revised:
20
06
2022
accepted:
20
09
2022
pubmed:
4
10
2022
medline:
4
10
2022
entrez:
3
10
2022
Statut:
ppublish
Résumé
Blocking the interaction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with its angiotensin-converting enzyme 2 (ACE2) receptor was proved to be an effective therapeutic option. Various protein binders as well as monoclonal antibodies that effectively target the receptor-binding domain (RBD) of SARS-CoV-2 to prevent interaction with ACE2 were developed. The emergence of SARS-CoV-2 variants that accumulate alterations in the RBD can severely affect the efficacy of such immunotherapeutic agents, as is indeed the case with Omicron that resists many of the previously isolated monoclonal antibodies. Here, we evaluate an ACE2-based immunoadhesin that we have developed early in the pandemic against some of the recent variants of concern (VoCs), including the Delta and the Omicron variants. We show that our ACE2-immunoadhesin remains effective in neutralizing these variants, suggesting that immunoadhesin-based immunotherapy is less prone to escape by the virus and has a potential to remain effective against future VoCs.
Identifiants
pubmed: 36188189
doi: 10.1016/j.isci.2022.105193
pii: S2589-0042(22)01465-1
pmc: PMC9514956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105193Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The Weizmann Institute has filed for a patent for the ACE2mod-Fc immunoadhesin.
Références
Nature. 2014 Oct 2;514(7520):47-53
pubmed: 25171469
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nature. 2016 Jul 28;535(7613):556-60
pubmed: 27338952
PLoS Pathog. 2010 May 27;6(5):e1000908
pubmed: 20523901
J Mol Biol. 2017 Sep 1;429(18):2825-2839
pubmed: 28736175
Annu Rev Biochem. 2008;77:363-82
pubmed: 18410248
N Engl J Med. 2021 Nov 18;385(21):1941-1950
pubmed: 34706189
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
EBioMedicine. 2022 Apr;78:103944
pubmed: 35465948
Nat Struct Mol Biol. 2010 Feb;17(2):248-50
pubmed: 20098425
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28046-28055
pubmed: 33093202
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Cell. 2020 Sep 17;182(6):1663-1673
pubmed: 32946786
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Sep 4;369(6508):1261-1265
pubmed: 32753553
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Nature. 2020 Aug;584(7819):120-124
pubmed: 32454512
J Chem Inf Model. 2022 Jan 24;62(2):412-422
pubmed: 34989238
PLoS Pathog. 2021 Apr 9;17(4):e1009501
pubmed: 33836016
J Infect. 2015 Jun;71 Suppl 1:S80-7
pubmed: 25922289
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Cell. 2020 Jul 9;182(1):73-84.e16
pubmed: 32425270
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Nature. 2003 Nov 27;426(6965):450-4
pubmed: 14647384
Cell Rep. 2020 Dec 22;33(12):108528
pubmed: 33326798
J Infect Dis. 2005 Feb 15;191(4):507-14
pubmed: 15655773
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63
pubmed: 27044104
JAMA. 2021 Feb 16;325(7):632-644
pubmed: 33475701
Cell Discov. 2020 Sep 29;6:68
pubmed: 33020722
Clin Infect Dis. 2022 Aug 24;75(1):e534-e535
pubmed: 35171987
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Cell Host Microbe. 2020 Sep 9;28(3):475-485.e5
pubmed: 32735849
Lancet Respir Med. 2020 Nov;8(11):1154-1158
pubmed: 33131609
Nat Commun. 2020 Jan 3;11(1):67
pubmed: 31900422
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Cardiovasc Res. 2007 Feb 1;73(3):463-9
pubmed: 17049503
Nature. 1989 Feb 9;337(6207):525-31
pubmed: 2536900
N Engl J Med. 2016 Nov 24;375(21):2019-2021
pubmed: 27959740
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Genome Res. 2004 Jun;14(6):1188-90
pubmed: 15173120
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
PLoS Pathog. 2016 Mar 30;12(3):e1005520
pubmed: 27028935
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nat Commun. 2020 Apr 24;11(1):2070
pubmed: 32332765
Sci Adv. 2022 Jul 15;8(28):eabn4188
pubmed: 35857504
Nat Commun. 2020 Aug 27;11(1):4303
pubmed: 32855401
Nat Med. 2017 Oct;23(10):1146-1149
pubmed: 28869611
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
Nat Med. 2017 Feb;23(2):185-191
pubmed: 28092665
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Nucleic Acids Res. 2004 Mar 19;32(5):1792-7
pubmed: 15034147
J Virol. 2015 Aug;89(15):7584-92
pubmed: 25972533
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
J Mol Med (Berl). 2006 Oct;84(10):814-20
pubmed: 16988814